You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
|
|---|---|
| Published in |
BMC Medicine, September 2017
|
| DOI | 10.1186/s12916-017-0932-3 |
| Pubmed ID | |
| Authors |
Dominic Thorrington, Edwin van Leeuwen, Mary Ramsay, Richard Pebody, Marc Baguelin |
| Abstract |
As part of the national seasonal influenza vaccination programme in England and Wales, children receive a quadrivalent vaccine offering protection against two influenza A strains and two influenza B strains. Healthy children receive a quadrivalent live attenuated influenza vaccine (QLAIV), whilst children with contraindications receive the quadrivalent inactivated influenza vaccine (QIIV). Individuals aged younger than 65 years in the clinical risk populations and elderly individuals aged 65+ years receive either a trivalent inactivated influenza vaccine (TIIV) offering protection from two A strains and one B strain or the QIIV at the choice of their general practitioner. The cost-effectiveness of quadrivalent vaccine programmes is an open question. The original analysis that supported the paediatric programme only considered a trivalent live attenuated vaccine (LAIV). The cost-effectiveness of the QIIV to other patients has not been established. We sought to estimate the cost-effectiveness of these programmes, establishing a maximum incremental total cost per dose of quadrivalent vaccines over trivalent vaccines. We used the same mathematical model as the analysis that recommended the introduction of the paediatric influenza vaccination programme. The incremental cost of the quadrivalent vaccine is the additional cost over that of the existing trivalent vaccine currently in use. Introducing quadrivalent vaccines can be cost-effective for all targeted groups. However, the cost-effectiveness of the programme is dependent on the choice of target cohort and the cost of the vaccines: the paediatric programme is cost-effective with an increased cost of £6.36 per dose, though an extension to clinical risk individuals younger than 65 years old and further to all elderly individuals means the maximum incremental cost is £1.84 and £0.20 per dose respectively. Quadrivalent influenza vaccines will bring substantial health benefits, as they are cost-effective in particular target groups. |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 20% |
| United Kingdom | 4 | 20% |
| Ireland | 3 | 15% |
| Portugal | 1 | 5% |
| Japan | 1 | 5% |
| Poland | 1 | 5% |
| Unknown | 6 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 60% |
| Scientists | 5 | 25% |
| Practitioners (doctors, other healthcare professionals) | 3 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 15 | 21% |
| Researcher | 11 | 15% |
| Student > Bachelor | 10 | 14% |
| Other | 8 | 11% |
| Student > Ph. D. Student | 8 | 11% |
| Other | 5 | 7% |
| Unknown | 15 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Mathematics | 6 | 8% |
| Nursing and Health Professions | 6 | 8% |
| Agricultural and Biological Sciences | 5 | 7% |
| Other | 8 | 11% |
| Unknown | 22 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2023.
All research outputs
#1,388,945
of 25,378,284 outputs
Outputs from BMC Medicine
#978
of 4,004 outputs
Outputs of similar age
#27,409
of 323,698 outputs
Outputs of similar age from BMC Medicine
#12
of 47 outputs
Altmetric has tracked 25,378,284 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,004 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,698 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.